Table 3.

Disease modifying drugs (DMDs) used in Behçet’s disease

Oral DMDs	Dose of drug
Azathioprine	2–3 mg/kg/day
Mycophenolate mofetil	2–3 gram/day
Methotrexate	20–25 mg/week
Tacrolimus	4–8 mg/day (depending on plasma trough levels)
Ciclosporin	2–5 mg/kg/day
Sulfasalazine	2–3 g/day
Dapsone	2–3 mg/kg/day
Thalidomide (exceptional use)	50–300 mg/day
Colchicine	0.5–2 mg/day
Prednisolone	Variable dose (depending on indication and stage of treatment)
Parenteral treatment
Cyclophosphamide	15 mg/kg (vasculitis regimens)
Anti-TNF α inhibitors
Infliximab	5 mg/kg at 0, 2 and 6 weeks then onceevery 8 weeks
Adalimumab	40 mg every 2 weeks
Etanercept	50 mg/week
Certolizumab	400 mg at 0, 2 and 4 weeks then once every 4 weeks
Rituximab	1 g at 0 and 2 weeks
Interferon α	Various regimens for Roferon A and pegylated interferon α 2b
Alemtuzumab	3 mg (day 1), 10 mg (day 3), 30 mg (day 5), 30 mg (day 8), 30 mg (day 10) and 30 mg (day 12)